Direct accesses
Go to main menu
Go to main content
Menu
Search the site
Contact
Careers
You are viewing the website in English
en
fr
Search the site
Who
we are
Company
Leadership
Collaborations
Diseases
we target
Diseases we target
Leber Hereditary Optic Neuropathy (LHON)
Retinitis Pigmentosa (RP)
Geographic Atrophy in Dry-AMD
Our
technologies
Technologies we are applying
Gene Therapy
Mitochondrial Targeting Sequence (MTS)
Optogenetics
Clinical development Summary
Investors
Company Overview
Financial press releases
Events & presentations
Stock information & Financial agenda
Governance
Documentation
Media
Company and personnel
Year
All
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
News type
All
Regulatory
Clinical
Conferences
Corporate
Finance
General Meeting
Product candidates
Science & Technology
Other
Subject
All
Company and personnel
GS010 - LUMEVOQ
GS030
Technologies
Other
28 February 2023
GenSight Biologics Announces its 2023 Financial Calendar
04 January 2023
GenSight Biologics to Present at Upcoming Investor Conferences
23 December 2022
GenSight Biologics secures €12 Million financing through a premium convertible notes issuance to an institutional investor and provides business update
04 November 2022
GenSight Biologics secures a €35 million credit facility from the European Investment Bank to support the launch of LUMEVOQ® in Europe
20 September 2022
GenSight Biologics to Present at Upcoming Industry and Investor Conferences
12 September 2022
GenSight Biologics strengthens its management team to support the launch of LUMEVOQ® in Europe
28 July 2022
GenSight Biologics Reports Interim Financial Results for the First Half of 2022
28 Oct 2021 - 29 Oct 2021
Cell UK by Oxford’s Global, London (UK) & Virtual
25 Oct 2021 - 28 Oct 2021
BIO-Europe 2021, Virtual
12 October 2021
GenSight Biologics Announces FDA Grant of Fast Track Designation for Optogenetic Therapy GS030 as Treatment for Retinitis Pigmentosa
1
2
3
4
5
6
…
15
View next 9 articles
Go back to the page of the page
